Developer docs
API playgroundTry for free, no card

Search company profiles

GeneDx

Full company profile

uuid00004w7

Namestring
GeneDx
Legal namestring
GeneDx, LLC
Websiteurl
genedx.com
Company typeenum
Public
Founded yearint
2000
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersStamford, United States
HQ citystring
Stamford
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical genetic testing, whole exome sequencing, whole genome sequencing, rare disease diagnostics, genomic data platform
Industry6 codes
PRIMARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)
SECONDARYHLAHAAAI
Genetic, Cytogenetic & Prenatal Screening IVD
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAACAK
Gene Therapy Analytical Testing & QC (potency, vg/ddPCR, infectivity, RCL/RCA)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAALAD
Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics)
SECONDARYHLAGADAG
Proteomics & Biomarker Analytical Testing
NAICS code2 codes
  • Medical Laboratories621511
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Medical Laboratories8071
Product category
Clinical Genomics / Rare Disease Genetic Testing Services
Social media profiles3 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Clinical genetic testing services
TypeTransaction Fee
Description

Primary revenue from clinical exome and genome sequencing tests billed to commercial insurance, Medicaid, Medicare, TRICARE, institutional accounts, or self-pay; recognized across all major payors as in-network provider.

genedx.com
2Biopharma data partnerships
TypeData Monetisation
Description

GeneDx collaborates with biopharma and researchers to share deidentified patient genomic and phenotypic data for drug discovery, clinical trial acceleration, and research; may receive compensation for data sharing and testing services.

genedx.com
3Health systems partnerships (Epic Aura)
TypeManaged Services
Description

Partnerships with large health systems for integrated precision medicine delivery across networks through Epic Aura EHR integration.

genedx.com
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Pricing details3 tiers
1Insurance-billed genetic testing
ModelOtherBilling cadencePay-as-you-go
Notes

Billed to commercial insurance (79% in-network), Medicaid (36–38 states), Medicare, TRICARE; coverage depends on plan, clinical indication, prior authorization, and medical necessity.

genedx.com
2Self-pay with financial assistance
ModelOtherBilling cadencePay-as-you-go
Notes

Competitive self-pay pricing, interest-free payment plans, and Financial Assistance Program available to reduce out-of-pocket costs for eligible families.

genedx.com
3Institutional billing
ModelOtherBilling cadenceMulti-year contract
Notes

Testing may be billed to institutional accounts in health systems and biopharma research collaborations.

genedx.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 3 records shown
1GeneDx Infinity
Description

Largest rare disease dataset platform powered by 2.5+ million genetic tests, nearly 1 million exomes and genomes, and over 8 million phenotypic data points.

genedx.com
+2 more records
Core offering1 text field

GeneDx is a clinical genomics laboratory that performs advanced whole exome and whole genome sequencing tests to diagnose rare and inherited diseases, with core products ExomeDx and GenomeDx (including rapid, ultraRapid, prenatal, and trio configurations). All tests are interpreted using the proprietary GeneDx Infinity rare disease dataset and AI-enabled variant classification, with results delivered through a provider portal and Epic Aura EHR integration.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 10 values shown
  • 60% of diagnosed patients experience a change in medical management
+9 more records
Product overview1 text field

GeneDx is a clinical genomics company offering a unified genetic testing platform centered on its massive rare disease dataset, GeneDx Infinity™. The platform is anchored by two core sequencing product families — GenomeDx™ (whole genome sequencing, including Rapid and ultraRapid variants) and ExomeDx™ (whole exome sequencing, including + mito, Rapid, and Prenatal variants) — supported by prenatal testing (Prenatal CMA, ExomeDx Prenatal, GenomeDx Prenatal), Trio testing (parental co-sampling for improved yield), and Targeted Variant Testing for cascade/familial variant confirmation. All products are accessed through the GeneDx Provider Portal (with Epic Aura EHR integration) and backed by 150+ genetic counselors for pre- and post-test support. Patient access programs (Financial Assistance, Epilepsy Partnership, Autism/SHANK3) and biopharma data services wrap around the testing portfolio. The Infinity™ dataset (2.5M+ tests, ~1M exomes/genomes, 8M+ phenotypic datapoints, 10.5K+ curated gene-disease associations) combined with AI-driven interpretation (originally augmented by the 2025 Fabric Genomics acquisition) powers variant classification across the entire test menu, with reanalysis included for no extra charge on exome/genome tests.

Product and service15 records
1ExomeDx
CategoryClinical genetic testing — whole exome sequencing
Description

Whole exome sequencing test analyzing protein-coding regions of ~20,000 genes, with sequence variants, copy-number variants, and optional mitochondrial variant detection. Available as proband, duo, or trio with standard results in as soon as 2 weeks. Diagnostic rate 25-35% across indications; 17% greater yield than standard testing.

2GenomeDx
CategoryClinical genetic testing — whole genome sequencing
Description

Whole genome sequencing test capturing coding, non-coding, intronic, and regulatory variants, CNVs, repeat expansions (10 conditions), mitochondrial variants, and structural variants. Available as proband, duo, or trio with standard results in 4 weeks. Diagnostic rate 40-50% across indications.

3Rapid and ultraRapid Genomic Sequencing
CategoryClinical genetic testing — rapid sequencing
Description

Rapid exome delivers provisional results within 7 days; ultraRapid genome delivers results as soon as 2 days for critically ill NICU/PICU and urgent cardiac care patients. Built for time-sensitive clinical scenarios.

4Prenatal Genetic Testing (Prenatal CMA, ExomeDx Prenatal, GenomeDx Prenatal)
CategoryClinical genetic testing — prenatal diagnostics
Description

Prenatal suite including Chromosomal Microarray Analysis (CMA), ExomeDx Prenatal, and GenomeDx Prenatal, with reflex to exome on the same sample. Supports amniotic fluid, CVS, and products of conception. Prenatal CMA diagnostic yield ~13%; prenatal exome 31% incremental yield; prenatal genome 19-36% incremental yield.

5Trio Testing
CategoryClinical genetic testing — trio/duo configurations
Description

Proband + duo or trio configurations across exome and genome tests, including parental samples for inheritance-based variant interpretation. Trio testing improves diagnostic yield by 7-15% and reduces inconclusive results by over 30% compared to gene panels.

6Targeted Variant Testing
CategoryClinical genetic testing — targeted/cascade variant testing
Description

Targeted genetic testing of previously identified familial variants for cascade testing, carrier testing, confirmatory testing, and mosaic variant analysis. Results in 2-3 weeks (3-4 weeks for variant confirmation). CLIA-confirmable.

7GeneDx Infinity
CategoryGenomic data and AI platform
Description

Proprietary rare disease dataset and AI-driven analytics platform built from 2.5M+ genetic tests, nearly 1M exomes and genomes, 8M+ phenotypic datapoints, and 10.5K+ curated gene-disease associations. Combines AI and clinical expertise to power variant interpretation across the test menu and to support biopharma drug discovery and clinical trial acceleration.

8GeneDx Provider Portal
CategoryProvider ordering platform
Description

Online provider-facing portal for ordering tests, viewing the test catalog, submitting specimens, accessing results, billing, and managing accounts. Integrated with Epic Aura EHR for in-workflow test ordering and result delivery.

9Epic Aura EHR Integration
CategoryEHR integration / health system channel
Description

Native Epic Aura EHR integration enabling providers to place GeneDx test orders directly within their Epic workflow, with streamlined results delivery and clinical decision support across health system networks.

10Biopharma Services
CategoryBiopharma data partnership services
Description

B2B offering that leverages the GeneDx Infinity rare disease dataset to accelerate drug discovery, clinical trial enrollment, and biopharma research partnerships through access to deeply phenotyped, deidentified rare disease genomic data.

11Newborn Screening Program
CategoryPopulation-scale newborn genetic screening
Description

Population-scale newborn genetic screening initiative partnering with state programs (e.g., Florida's Sunshine Genetics Program) to expand screening from ~60 conditions to nearly 900 rare genetic diseases using whole genome sequencing.

12Epilepsy Partnership Program
CategoryPatient access program
Description

Patient access program expanding access to exome sequencing for eligible children with epilepsy, even when insurance coverage is limited.

13Autism Partnership Program / SHANK3 Genetic Testing
CategoryPatient access program
Description

Patient access solution offering guideline-backed exome testing with financial support for eligible patients meeting eight clinical criteria.

14Financial Assistance Program
CategoryPatient financial assistance
Description

Program to reduce out-of-pocket costs for patients, complementing Medicaid coverage in 36-37 states and broad in-network commercial coverage. Includes interest-free payment plans for eligible patients and families.

15Genetic Counseling Support
CategoryClinical support services
Description

Clinical support service from 150+ genetic counselors providing pre-order guidance, mid-process assistance, and post-result interpretation including pre-test patient education and post-test genetic counseling for providers and patients.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2026-06-09
Description

GeneDx management participated in the Goldman Sachs 47th Annual Global Healthcare Conference (June 8–10, 2026, Miami, FL), including a fireside chat on June 9 featuring CFO Kevin Feeley discussing expansion into pediatric neurology markets.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-05-01
Description

AI-driven genomic interpretation company acquired by GeneDx in April/May 2025 for $33.2–$51M (cash upfront of ~$33M with earn-outs). Q1 2026 results revealed $31.2–$31.3M impairment charge (94% write-off), leading to multi-class-action lawsuits.

Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Five-year Florida pilot program at Tampa General Hospital partnering with GeneDx to expand newborn screening from 60 to nearly 900 rare genetic diseases via whole genome sequencing. Spearheaded by State Rep. Adam Anderson following personal loss of his son to Tay-Sachs; backed by tens of millions in state investment.

4A.J. Anderson Foundation / Florida Institute for Pediatric Rare Diseases at FSU
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Expanded partnership co-hosting a rare disease conference in Pinellas County, FL, supporting the Sunshine Genetics Act and newborn whole-genome sequencing pilot program for genetic screening initiatives.

news.fsu.edu
Strategic tierMinorTypeGTM or Marketing Partner
Description

Sponsored Ultragenyx's Rare Bootcamp event in Boston in April 2026, a free multi-day forum helping families of children with rare diseases learn about drug development; co-sponsored with Alexion, BioMarin, and BridgeBio.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Partner telehealth service enabling patients without local licensed healthcare providers to access GeneDx exome testing through Genome Medical's clinician network.

Strategic tierFlagshipTypeTechnology or Integration
Description

Epic Aura EHR integration enables providers to place GeneDx orders directly within their Epic workflow, supporting streamlined ordering and results delivery across health systems.

Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Carelon's new outpatient genome coverage policy cited by Piper Sandler as a potential structural de-risking event, expected to drive approximately $100 in incremental average selling price by the second half of 2027.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Specialized clinical genetics lab with strong oncology and reproductive health testing; overlaps with GeneDx in prenatal and rare-disease exome/genome testing.

TypeBroad incumbent
Description

Oncology-focused clinical lab expanding into broader molecular and rare-disease genomics; overlaps in hospital channel and biopharma services.

TypeDirect peer
Description

Clinical genetics lab offering whole-exome, whole-genome, and panel tests with a similar provider portal and payor-billing model; comparable in pediatric rare-disease positioning.

TypeDirect peer
Description

Clinical genetic testing company offering exome, genome, and panel-based testing with a comparable provider-facing model; direct competitor in rare-disease and pediatric genetic diagnostics.

TypeBroad incumbent
Description

Established clinical genetics company with hereditary cancer, pharmacogenomics, and growing rare-disease offerings; broader menu but overlapping provider and payor channels.

TypeEmerging player
Description

Genomic diagnostics company combining proprietary testing with AI-driven analytics; comparable in using growing genomic datasets to power clinical interpretation and biopharma partnerships.

TypeBroad incumbent
Description

Largest U.S. clinical lab with broad molecular and genomic testing; entering incoming President Mark Gardner's former employer — directly competitive in exome/genome and payor contracts.

TypeBroad incumbent
Description

Major clinical lab with growing genomics and oncology offerings (including OmniSeq acquisition); broad hospital and payor channel that increasingly competes for exome/genome volume.

9Tempus AI
TypeEmerging player
Description

AI-driven precision medicine company combining multimodal clinical and genomic data for diagnostics and biopharma; comparable in using AI/large datasets to drive clinical insights.

TypeOthers
Description

Long-read sequencing technology provider enabling high-accuracy exome/genome workflows; adjacent enabling technology for clinical labs like GeneDx.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability8 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles19 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors17 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

GeneDx

Clinical Genomics / Rare Disease Genetic Testing Servicesgenedx.com

GeneDx firmographics

Firmographics
Name
GeneDx
Legal name
GeneDx, LLC
Website
https://genedx.com
Company type
Public
Founded year
2000
Operating status
Operating
Headcount range
1,001–5,000 employees
Ownership category
akta.pro rank

GeneDx industry classification

Industry
Product category
Clinical Genomics / Rare Disease Genetic Testing Services
NAICS
Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)
SECONDARYHLAHAAAI
Genetic, Cytogenetic & Prenatal Screening IVD
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAACAK
Gene Therapy Analytical Testing & QC (potency, vg/ddPCR, infectivity, RCL/RCA)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAALAD
Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics)
SECONDARYHLAGADAG
Proteomics & Biomarker Analytical Testing

Keywords

  • Clinical genetic testing
  • Whole exome sequencing
  • Whole genome sequencing
  • Rare disease diagnostics
  • Genomic data platform

Where GeneDx is headquartered

Location

Headquarters

HQ city
Stamford
HQ country
United States
HQ region
North America

Offices1 record

Markets served

GeneDx business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Clinical genetic testing services: Primary revenue from clinical exome and genome sequencing tests billed to commercial insurance, Medicaid, Medicare, TRICARE, institutional accounts, or self-pay; recognized across all major payors as in-network provider.
  2. Biopharma data partnerships: GeneDx collaborates with biopharma and researchers to share deidentified patient genomic and phenotypic data for drug discovery, clinical trial acceleration, and research; may receive compensation for data sharing and testing services.
  3. Health systems partnerships (Epic Aura): Partnerships with large health systems for integrated precision medicine delivery across networks through Epic Aura EHR integration.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goInsurance-billed genetic testing
OtherPay-as-you-goSelf-pay with financial assistance
OtherMulti-year contractInstitutional billing

Go-to-market motion1 record

Distribution channels5 records

Marketing channels9 records

GeneDx product offering

Product offering

Core offering

GeneDx is a clinical genomics laboratory that performs advanced whole exome and whole genome sequencing tests to diagnose rare and inherited diseases, with core products ExomeDx and GenomeDx (including rapid, ultraRapid, prenatal, and trio configurations). All tests are interpreted using the proprietary GeneDx Infinity rare disease dataset and AI-enabled variant classification, with results delivered through a provider portal and Epic Aura EHR integration.

Product overview

GeneDx is a clinical genomics company offering a unified genetic testing platform centered on its massive rare disease dataset, GeneDx Infinity™. The platform is anchored by two core sequencing product families — GenomeDx™ (whole genome sequencing, including Rapid and ultraRapid variants) and ExomeDx™ (whole exome sequencing, including + mito, Rapid, and Prenatal variants) — supported by prenatal testing (Prenatal CMA, ExomeDx Prenatal, GenomeDx Prenatal), Trio testing (parental co-sampling for improved yield), and Targeted Variant Testing for cascade/familial variant confirmation. All products are accessed through the GeneDx Provider Portal (with Epic Aura EHR integration) and backed by 150+ genetic counselors for pre- and post-test support. Patient access programs (Financial Assistance, Epilepsy Partnership, Autism/SHANK3) and biopharma data services wrap around the testing portfolio. The Infinity™ dataset (2.5M+ tests, ~1M exomes/genomes, 8M+ phenotypic datapoints, 10.5K+ curated gene-disease associations) combined with AI-driven interpretation (originally augmented by the 2025 Fabric Genomics acquisition) powers variant classification across the entire test menu, with reanalysis included for no extra charge on exome/genome tests.

Differentiator

Problem solved

Functional benefit

Brands

  • GeneDx Infinity: Largest rare disease dataset platform powered by 2.5+ million genetic tests, nearly 1 million exomes and genomes, and over 8 million phenotypic data points.
  • ExomeDx
  • GenomeDx

Products and services

  • ExomeDx Whole exome sequencing test analyzing protein-coding regions of ~20,000 genes, with sequence variants, copy-number variants, and optional mitochondrial variant detection. Available as proband, duo, or trio with standard results in as soon as 2 weeks. Diagnostic rate 25-35% across indications; 17% greater yield than standard testing.
  • GenomeDx Whole genome sequencing test capturing coding, non-coding, intronic, and regulatory variants, CNVs, repeat expansions (10 conditions), mitochondrial variants, and structural variants. Available as proband, duo, or trio with standard results in 4 weeks. Diagnostic rate 40-50% across indications.
  • Rapid and ultraRapid Genomic Sequencing Rapid exome delivers provisional results within 7 days; ultraRapid genome delivers results as soon as 2 days for critically ill NICU/PICU and urgent cardiac care patients. Built for time-sensitive clinical scenarios.
  • Prenatal Genetic Testing (Prenatal CMA, ExomeDx Prenatal, GenomeDx Prenatal) Prenatal suite including Chromosomal Microarray Analysis (CMA), ExomeDx Prenatal, and GenomeDx Prenatal, with reflex to exome on the same sample. Supports amniotic fluid, CVS, and products of conception. Prenatal CMA diagnostic yield ~13%; prenatal exome 31% incremental yield; prenatal genome 19-36% incremental yield.
  • Trio Testing Proband + duo or trio configurations across exome and genome tests, including parental samples for inheritance-based variant interpretation. Trio testing improves diagnostic yield by 7-15% and reduces inconclusive results by over 30% compared to gene panels.
  • Targeted Variant Testing Targeted genetic testing of previously identified familial variants for cascade testing, carrier testing, confirmatory testing, and mosaic variant analysis. Results in 2-3 weeks (3-4 weeks for variant confirmation). CLIA-confirmable.
  • GeneDx Infinity Proprietary rare disease dataset and AI-driven analytics platform built from 2.5M+ genetic tests, nearly 1M exomes and genomes, 8M+ phenotypic datapoints, and 10.5K+ curated gene-disease associations. Combines AI and clinical expertise to power variant interpretation across the test menu and to support biopharma drug discovery and clinical trial acceleration.
  • GeneDx Provider Portal Online provider-facing portal for ordering tests, viewing the test catalog, submitting specimens, accessing results, billing, and managing accounts. Integrated with Epic Aura EHR for in-workflow test ordering and result delivery.
  • Epic Aura EHR Integration Native Epic Aura EHR integration enabling providers to place GeneDx test orders directly within their Epic workflow, with streamlined results delivery and clinical decision support across health system networks.
  • Biopharma Services B2B offering that leverages the GeneDx Infinity rare disease dataset to accelerate drug discovery, clinical trial enrollment, and biopharma research partnerships through access to deeply phenotyped, deidentified rare disease genomic data.
  • Newborn Screening Program Population-scale newborn genetic screening initiative partnering with state programs (e.g., Florida's Sunshine Genetics Program) to expand screening from ~60 conditions to nearly 900 rare genetic diseases using whole genome sequencing.
  • Epilepsy Partnership Program Patient access program expanding access to exome sequencing for eligible children with epilepsy, even when insurance coverage is limited.
  • Autism Partnership Program / SHANK3 Genetic Testing Patient access solution offering guideline-backed exome testing with financial support for eligible patients meeting eight clinical criteria.
  • Financial Assistance Program Program to reduce out-of-pocket costs for patients, complementing Medicaid coverage in 36-37 states and broad in-network commercial coverage. Includes interest-free payment plans for eligible patients and families.
  • Genetic Counseling Support Clinical support service from 150+ genetic counselors providing pre-order guidance, mid-process assistance, and post-result interpretation including pre-test patient education and post-test genetic counseling for providers and patients.

Quantifiable outcome

  • 60% of diagnosed patients experience a change in medical management
  • +9 more outcomes

Companies that use GeneDx

Customer profile

Named customers7 records

Segments5 records

Ideal customer profiles4 records

GeneDx technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability8 records

Feature8 records

GeneDx partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered minor, flagship and core.

  • Goldman Sachs (Global Healthcare Conference)minorGTM or Marketing Partner · 9 June 2026GeneDx management participated in the Goldman Sachs 47th Annual Global Healthcare Conference (June 8–10, 2026, Miami, FL), including a fireside chat on June 9 featuring CFO Kevin Feeley discussing expansion into pediatric neurology markets.
  • Fabric GenomicsflagshipStrategic or Co-development Partner · 1 May 2025AI-driven genomic interpretation company acquired by GeneDx in April/May 2025 for $33.2–$51M (cash upfront of ~$33M with earn-outs). Q1 2026 results revealed $31.2–$31.3M impairment charge (94% write-off), leading to multi-class-action lawsuits.
  • Tampa General Hospital / Florida (Sunshine Genetics Newborn Screening Program)flagshipStrategic or Co-development PartnerFive-year Florida pilot program at Tampa General Hospital partnering with GeneDx to expand newborn screening from 60 to nearly 900 rare genetic diseases via whole genome sequencing. Spearheaded by State Rep. Adam Anderson following personal loss of his son to Tay-Sachs; backed by tens of millions in state investment.
  • A.J. Anderson Foundation / Florida Institute for Pediatric Rare Diseases at FSUcoreStrategic or Co-development PartnerExpanded partnership co-hosting a rare disease conference in Pinellas County, FL, supporting the Sunshine Genetics Act and newborn whole-genome sequencing pilot program for genetic screening initiatives.
  • Ultragenyx (Rare Bootcamp)minorGTM or Marketing PartnerSponsored Ultragenyx's Rare Bootcamp event in Boston in April 2026, a free multi-day forum helping families of children with rare diseases learn about drug development; co-sponsored with Alexion, BioMarin, and BridgeBio.
  • Genome MedicalcoreChannel Partner/ Reseller/ DistributorPartner telehealth service enabling patients without local licensed healthcare providers to access GeneDx exome testing through Genome Medical's clinician network.
  • Epic (Epic Aura EHR integration)flagshipTechnology or IntegrationEpic Aura EHR integration enables providers to place GeneDx orders directly within their Epic workflow, supporting streamlined ordering and results delivery across health systems.
  • Carelon (coverage policy)flagshipStrategic or Co-development PartnerCarelon's new outpatient genome coverage policy cited by Piper Sandler as a potential structural de-risking event, expected to drive approximately $100 in incremental average selling price by the second half of 2027.

Scale indicators12 records

Recent moves6 records

Expansion highlights6 records

GeneDx competitors and assessment

Company assessment

Direct peers

  • Natera: Specialized clinical genetics lab with strong oncology and reproductive health testing; overlaps with GeneDx in prenatal and rare-disease exome/genome testing.
  • Fulgent Genetics: Clinical genetics lab offering whole-exome, whole-genome, and panel tests with a similar provider portal and payor-billing model; comparable in pediatric rare-disease positioning.
  • Invitae: Clinical genetic testing company offering exome, genome, and panel-based testing with a comparable provider-facing model; direct competitor in rare-disease and pediatric genetic diagnostics.

Broad incumbents

  • NeoGenomics: Oncology-focused clinical lab expanding into broader molecular and rare-disease genomics; overlaps in hospital channel and biopharma services.
  • Myriad Genetics: Established clinical genetics company with hereditary cancer, pharmacogenomics, and growing rare-disease offerings; broader menu but overlapping provider and payor channels.
  • Quest Diagnostics: Largest U.S. clinical lab with broad molecular and genomic testing; entering incoming President Mark Gardner's former employer — directly competitive in exome/genome and payor contracts.
  • Labcorp: Major clinical lab with growing genomics and oncology offerings (including OmniSeq acquisition); broad hospital and payor channel that increasingly competes for exome/genome volume.

Emerging players

  • Veracyte: Genomic diagnostics company combining proprietary testing with AI-driven analytics; comparable in using growing genomic datasets to power clinical interpretation and biopharma partnerships.
  • Tempus AI: AI-driven precision medicine company combining multimodal clinical and genomic data for diagnostics and biopharma; comparable in using AI/large datasets to drive clinical insights.

Others

  • Pacific Biosciences: Long-read sequencing technology provider enabling high-accuracy exome/genome workflows; adjacent enabling technology for clinical labs like GeneDx.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

GeneDx social profiles

Digital presence

GeneDx compliance and trust

Trust signal

Compliance3 records

GeneDx financial estimates

Financial estimate

Revenue estimate

Valuation estimate

GeneDx leadership team

Management profile

Number of profiles

Profiles19 records

GeneDx subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

GeneDx funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors17 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

GeneDx M&A and investment

M&A and investment

M&A3 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GeneDx

What does GeneDx do?

GeneDx is a clinical genomics laboratory that performs advanced whole exome and whole genome sequencing tests to diagnose rare and inherited diseases, with core products ExomeDx and GenomeDx (including rapid, ultraRapid, prenatal, and trio configurations). All tests are interpreted using the proprietary GeneDx Infinity rare disease dataset and AI-enabled variant classification, with results delivered through a provider portal and Epic Aura EHR integration.

Is GeneDx a public or private company?

GeneDx is a public company. It is classified as public and is currently operating.

When was GeneDx founded?

GeneDx was founded in 2000. It employs 1,001 to 5,000 people.

Where is GeneDx based?

GeneDx is headquartered in Stamford, United States, in the North America region.

How does GeneDx make money?

Three revenue lines are on record. Clinical genetic testing services are the primary driver. The others are biopharma data partnerships and health systems partnerships (Epic Aura).

Who are GeneDx's main competitors?

Direct peers on record are Natera, Fulgent Genetics and Invitae. Broad incumbents are NeoGenomics, Myriad Genetics, Quest Diagnostics and Labcorp. Emerging players are Veracyte and Tempus AI. Pacific Biosciences is listed as an others.

Does GeneDx have an API?

No public API is recorded for GeneDx.

What industry is GeneDx in?

GeneDx's product category is Clinical Genomics / Rare Disease Genetic Testing Services. Its primary akta.pro industry code is HLAAACAE, Gene Therapy for Rare/Monogenic Diseases, with a secondary code of HLAGADAF, Molecular & Genetic Testing (PCR/NGS/qPCR). Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
American Banking and Market NewsGagnon Advisors LLC Sells 14,846 Shares of GeneDx Holdings Corp. $WGSGagnon Advisors LLC sold 14,846 GeneDx shares in Q3, reducing its stake by 8.3% to 163,024 shares. The firm's position is worth $11.787 million, and insiders sold 19,206 shares over the quarter. Analysts rate GeneDx a Moderate Buy with an average target of $90.14.Stock TitanGeneDx plans long-read genome test access by year-endGeneDx announced plans to expand its genome testing portfolio with long-read whole genome sequencing for rare disease diagnosis. The company will offer the technology upfront for eligible patients, aiming to reduce sequential testing and accelerate diagnosis. Early access is planned by year-end.YahooGeneDx Expands Diagnostic Leadership with Long-Read Genome Sequencing, Advancing Rare Disease DiagnosisGeneDx announced plans to add long-read whole genome sequencing to its rare disease diagnostic portfolio, targeting complex genetic variation. The company will offer the technology upfront for eligible patients, with an early access program available by year-end. The initiative aims to reduce sequential testing and accelerate diagnoses.Stock TitanGeneDx Plans Long-Read Genome Sequencing Early AccessGeneDx announced plans to offer long-read whole genome sequencing upfront for eligible patients, aiming to reduce sequential testing and accelerate rare disease diagnosis. The early access program will be available by year-end, leveraging its phenotype-driven approach and clinical expertise.MarketBeatGeneDx (WGS) Projected to Announce Quarterly Earnings on TuesdayGeneDx is projected to announce Q3 2026 earnings on Tuesday, October 27th, with analysts expecting EPS of $0.0729 and revenue of $122.93 million. The company's stock opened at $66.29, and insiders sold 19,206 shares in the last 90 days. Analysts have a consensus rating of Moderate Buy with a target price of $90.86.EIN PresswireGeneDx Advances Clinical Adoption of Genomic Medicine with 27 Abstracts at ASHG 2026GeneDx announced 27 accepted abstracts at ASHG 2026, covering exome and genome sequencing in rare disease, autism, and newborn screening. The research includes studies on over 100,000 autism patients and the GUARDIAN study with 19,000 newborns. The company aims to make genomic testing more accessible and actionable.Stock TitanGeneDx has 27 abstracts accepted for ASHG 2026GeneDx announced 27 accepted scientific abstracts at the ASHG 2026 Annual Meeting, covering genomic testing research. The abstracts span five areas, including AI-assisted CNV prioritization, autism exome sequencing in over 100,000 individuals, and newborn screening in 19,000 diverse newborns. Results remain under embargo until presentation.FinancialContent Business PageGeneDx Advances Clinical Adoption of Genomic Medicine with 27 Abstracts at ASHG 2026GeneDx announced 27 accepted abstracts at ASHG 2026, covering exome and genome sequencing research. The abstracts include studies on autism diagnostic yield from over 100,000 individuals and newborn screening findings from the GUARDIAN study. The company aims to advance genomic medicine through these findings.MarketBeatGeneDx Holdings Corp. $WGS Shares Acquired by Assenagon Asset Management S.A.Assenagon Asset Management increased its GeneDx stake by 108.4% in Q3, holding 632,413 shares worth $45.7 million. CEO Katherine Stueland and CFO Kevin Feeley sold shares for tax withholding, and analysts rate the stock a Moderate Buy with a $90.86 target.American Banking and Market NewsAnalyzing Brookdale Senior Living (NYSE:BKD) and GeneDx (NASDAQ:WGS)GeneDx and Brookdale Senior Living are compared on valuation, profitability, and analyst ratings. Brookdale Senior Living has a stronger consensus rating and higher upside potential, while GeneDx beats on 8 of 15 factors. Analysts favor Brookdale Senior Living as the more favorable investment.